Pharmacyclics Inc

Pharmacyclics — ASCO 2010

21 slides from Pharmacyclics's conference presentation, Jun 7, 2010

  1. Slide 1: Btk Inhibitor PCI-32765 Monotherapy Induces Objective Responses in Relapsed Aggressive NHL

    @pharmacyclics: Btk Inhibitor PCI-32765 Monotherapy Induces Objective Responses in Patients with Relapsed Aggressive NHL: Evidence of Antitumor Activity from a Phase! Study R. Advani', J. Sharman?, S. Smith, D. Pollyea’, T. Boyd*, B: Grant®, K. Kolibaba®, J. Buggy’, A. Hamdy? and N. Fowler Stanford

  2. Slide 2: B Cell Receptor Signaling Pathway

    B Cell Receptor Signaling Pathway B cell receptor B cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation BCR signaling requires Bruton's Tyrosine Kinase (Btk) Mutations in Btk prevent B cell maturation Btk inhibition blocks BCR signaling and induces apoptosis _ {|

  3. Slide 3: PCI-32765 Novel Small Molecule Btk Inhibitor

    PCI-32765 Novel Small Molecule Btk Inhibitor =Forms a specific and irreversible o’h\ J bond with cysteine-481 in Btk fr. =Potent Btk inhibition i rr *ICsq = 0.5 nM Tdag! "Orally available N “= PCI-32765 3 Qeharmacyclics

  4. Slide 4: PCI-32765 Preclinical Data

    PCI-32765 Precl = Invitro data = Blocks BCR-stimulated activation of NF-kB and ERK = Inhibits growth and induces apoptosis of B cell lymphoma cell lines = Does not affect T cell function * Active in multiple in vivo models = Transgenic murine model of BCR-driven lymphoma = Spontaneous B cell lymphom

  5. Slide 5: Study Design

    Study Design *Ongoing Phase I, multicenter, open-label, dose-escalation study of PCI-32765 in recurrent B cell lymphoma =Dosing = Cohorts n > 6 patients = If > 2 DLTs are observed Sunnie eye 1, MTD will be established as the previous cohort = Dosing until PD = 1.25, 2.5, 5.0, 8.3, 12.5, 17.5 mg/kg/d

  6. Slide 6: Objectives

    Objectives = Primary Objectives: = Establish the safety and the MTD = Determine the pharmacokinetics of study drug = Measure the pharmacodynamic parameters, including drug occupancy of Btk "Secondary Objective: = Evaluate tumor response 6 Qeharmacyclics

  7. Slide 7: Eligibility: B cell NHL including CLL/SLL and WM

    =Ig* Surface Antigen B cell NHL including CLL/SLL and WM = Measurable disease = 2 2.cm diameter for NHL or 2 5000 leukemia cells/mm? for CLL or IgM level 2 1000 mg/dL + BM infiltration for WM =Prior treatment: 2 1 and <4 =No known CNS involvement or uncontrolled infection "ECOG< 1 =Laboratory: = Pla

  8. Slide 8: Results: Baseline Patient Characteristics

    Results: Baseline Patient Characteristics n=47 Median age, years (range) 65 (41-82) Histology at diagnosis n(%) FL 16 (34) CLL/SLL 15 (32) DLBCL 7(15) mci (9) MzL 4(9) WM 1(2) Median prior therapies, (range) 3 (1-4) Therapy n(%) Rituximab 43 (91) Alkylators 40 (85) Nucleoside analogs 27(57) Anthracy

  9. Slide 9: Results: Enrollment

    Results: Enrollment Total n= 47 Cohorts (mg/kg/day) hk 125 ¥ 1: 2.5 9 5.0 6 83 8 8.3 (Continuous dosing) 10 Ve 12.5 Disposition ‘On study 25 Discontinuation of drug 22 Disease progression 13 Patient decision 2 Pi decision ed SAE 4 DLT 2 ° Qeharmacyclics

  10. Slide 10: Results: Frequency of Adverse Events

    Results: Frequency of Adverse Events n=47 n(%) Any AE 47 (100) Grade 2 3 AE 18 (38) Any Related AE 38 (81) Related Grade 2 3 AE 6 (13) Any SAE 13 (28) Related SAEs 2(4) Deaths* 4(9) Note: Counts in the table represent number of patients “All deaths due to documented disease progression 40 Qeharmacyc

  11. Slide 11: Results: All Patients with Related AEs by Dose Level

    Results: All Patients with Related AE’s by Dose Level 1 " Ml wv cD v 1.25mgikg | 2.5mgikg | S5mgikg | 8.3mg/kg | 83mgkkg | 12.5mg/kg n=7 n=! n=6 n= n=10 n=7 Grade 4 7 7 5 5 @ 4 Grade 2 5 4 3 3 1 3 Grade 3 oO 3 0 3 0 Oo Grade 4 0 2 0 0 0 0 * No consistent relationship between dose level and observed

  12. Slide 12: Results: Non-Hematologic Adverse Events

    Results: n = 47 All Non Hematologic 100 20 m Grade 3 oa ™ Grade 2 “0 ™ Grade 1 =] a LTT nen pgengaliyyy ey 2 Qeharmacyclics

  13. Slide 13: Results: All laboratory AEs

    Results: All laboratory AE’s (n=47) =No change in circulating normal B, T or NK cells in peripheral blood =No consistent changes in hepatic and renal functions =No consistent hematologic laboratory findings =No consistent dose effect relationship B Qeharmacyclics

  14. Slide 14: Durable and Dose-Dependent Pharmacodynamic Effects with PCI-32765

    Durable and Dose-Dependent Pharmacodynamic Effects with PCI-32765 Btk Occupancy in Peripheral Blood Cells fies brerace (Probe Assay) peisems pei Se7es 100: 4 DN 7 co ‘=| = 3 we Fa] 3 a 8 a 3 8 = 5 & * A x A 1... oo Pre 4h 24h Pre 4h 24h Pre 4h 24h Pre 4h 24h Pre 4h 24h Pre 4h 24h Cohort! Cohort I Co

  15. Slide 15: Pharmacokinetics: Tmax and AUC

    = Mean Tmax not dose dependent - 1.0 to 2.3 h after oral delivery =Meant,,. increased with increasing dose - 6.3 to 10.8h = Day-8 AUC,.»4, greater than Day-1 AUC, ing by 75% to 250% = Btk full occupancy occurred at AUC) ing Values 2 455 nMeh = All patients given 2.5 mg/kg hada Day-8 AUC value > 557

  16. Slide 16: Clinical Finding

    Clinical Finding Dose #of Cohort! (mg/kg) Pts | CR PR sD PD NE 1 1.25 7 2 1 4 " 25 9 4 1 2 2 um 5.0 6 1 2 1 1 1 IV 8.3 8 1 2 3 A 1 Continuous 8.3 10 5 3 1 t Total 40 2 15 9 9 5 5% | 37.5% | 22.5% | 22.5% | 12.5% 46 1 Reponses in 9! dose-level cohort (12.5 mg/kg) have yet to be determined Qeharmacycl

  17. Slide 17: Response by Histology

    Response by Histology Cohorts 1-4 and Contint #of Clinical Finding! Histology Pts RR? CR PR SD PD NE° Chronic lymphocytic leukemia | (CLL/SLL) 13 82% 1 8 2 2 Mantle cell lymphoma (MCL) 4 75% | 1 2 | 4 Diffuse large B-cell lymphoma forged 6 | 17% 1/4] 4 Follicular lymphoma (FL) 13 27% 3 4 4 2 Margina

  18. Slide 18: [Becsctamsy

    n=32! [Becsctamsy + Spatients not included dueto lack of tumor measurements (2PD, 2 SAE, 19 2DLT, 1 Pt decision, 1 pending) pharmacyclics

  19. Slide 19: Duration of treatment by dose

    Dose (mg/kg/day) 19 © a © a ° Pe ° o 12.5 8.3- cD = . On study n=25 it r * Partial or complete response * Stable disease ‘Median number of cydes for Cohorts = LAs 4.range (0t0 10) 0 5 10 15 20 2 30 35 40 45 50 55 Duration (wks) Qeharmacyclics

  20. Slide 20: Results: CLL Response in Circulating Cells

    Results: CLL Response in Circulating Cells Over = Transient increases in circulating CLL cells associated with observed decrease in lymph node size Patient 073001 20 Qeharmacyclics

  21. Slide 21: Conclusions

    =Btk inhibition in B-cell malignancies is a novel and promising treatment approach = PCI-32765 is first-in-class potent inhibitor of Btk that demonstrated clinical benefit with single agent oral dosing. = Well tolerated with minimal toxicities at doses up to 12.5 mg/kg/day, MTD not reached ™ Respons

Pharmacyclics — ASCO 2010 on 6ix